The majority of PCa is diagnosed as adenocarcinomas (i.e., prostate adenocarcinoma [PRAD]) expressing the androgen receptor (AR), with less than 1% as de novo neuroendocrine PCa (NEPC), which is AR–. Here, AR is linked to adenocarcinoma.